Phaseline

Companies › Ocumension Therapeutics (Suzhou)

Ocumension Therapeutics (Suzhou): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Ophthalmology; next expected readout Jan 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OT202
Unclear mechanism for dry eye treatment
–Phase 3Dry EyeJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07740564OT202Phase 3Dry EyeOphthalmologyJan 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

ReGenTree Ocus Innovation Ireland Alkeus Pharmaceuticals Laboratorios Sophia S.A de C.V. Cloudbreak Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.